Prelude Therapeutics' GAAP loss for 2021 was $111.694 million, up 96.2% from $56.929 million the previous year.
Prelude Therapeutics' GAAP loss for 2021 was $111.694 million, up 96.2% from $56.929 million the previous year.
Prelude Therapeutics reported for 2021
Prelude Therapeutics' GAAP loss for 2021 was $111.694 million, up 96.2% from $56.929 million the previous year. Source: 
investors.preludetx.com
investors.preludetx.com
English (US) 